Objective
to test whether postprocedural anticoagulation (PPA) was superior to no PPA after primary PCI for STEMI
Study
investigator-initiated multicentre (China) placebo-controlled randomised trial
Population
patients undergoing primary PCI receiving low dose PPA (iv UFH, iv bivalirudin or subcutaneous enoxaparin) for at least 48 hours
Endpoints
composite of all-cause death, MI, stroke, stent thrombosis (definite) or urgent revascularisation within 30 days
/medias/8706/25-T015_Yan_02.jpg)
/medias/8709/25-T015_Yan_01.jpg)
Conclusion
anticoagulation after primary PCI for STEMI did not reduce 30-day ischaemic events
Yan et al.; Circulation 2024;149:1258-1267